Incidence, Clinical Characteristics and Predictors of Statin Intolerance Among Patients Initiated on Statin Therapy: A Prospective Cohort Study
Background: Statin intolerance is an important cause of inadequate lipid-lowering therapy and premature treatment discontinuation. Reported prevalence varies widely because definitions, symptom ascertainment, and diagnostic confirmation differ substantially between studies. Objective: To determine the incidence of confirmed statin intolerance, compare estimates obtained using different operational definitions, examine associations with statin type and intensity, and identify independent predictors of intolerance. Materials and Methods: This prospective observational longitudinal cohort study included 500 statin-naïve adults with an established indication for lipid-lowering therapy at a tertiary care centre. Participants were followed for 12 months using structured clinical assessment and laboratory monitoring. Suspected intolerance was evaluated by symptom characterization, creatine kinase and hepatic testing, exclusion of secondary causes, dechallenge, and rechallenge where appropriate. Statin intolerance was classified according to National Lipid Association (NLA), International Lipid Expert Panel (ILEP), European Atherosclerosis Society (EAS), and Luso-Latin American Consortium/Canadian Consensus Working Group (LLAC/CCWG) criteria. Multivariable logistic regression was used to identify predictors of confirmed intolerance. Results: Of 500 enrolled participants, 462 completed follow-up. Ninety-seven participants (21.0%) reported at least one suspected statin-related adverse effect, whereas 48 met the NLA definition of confirmed intolerance, giving a cumulative incidence of 10.4% (95% CI 7.9–13.5). Estimates varied from 8.0% with LLAC/CCWG criteria to 11.3% with ILEP criteria. Complete intolerance occurred in 3.7% and partial intolerance in 6.7%. Intolerance was more frequent with high-intensity therapy than moderate-intensity therapy (14.8% vs 7.9%; p=0.002). Concomitant CYP3A4-interacting medication was associated with an intolerance rate of 21.1% compared with 8.9% in its absence (p=0.003). Independent predictors included prior exposure to negative information regarding statins (adjusted OR 3.04), CYP3A4-interacting medication (aOR 2.76), vitamin D deficiency (aOR 2.41), high-intensity statin therapy (aOR 2.18), age ≥65 years (aOR 1.94), and female sex (aOR 1.87). Conclusion: Approximately one in ten statin-naïve patients developed confirmed statin intolerance, substantially fewer than the proportion reporting suspected adverse effects. Diagnostic definition materially altered the estimated frequency. Several predictors were potentially modifiable, supporting systematic evaluation before permanent statin discontinuation